19 May 2016
The results from an analysis of miR 31-3p expression for metastatic colorectal cancer (mCRC) patients enrolled in the FIRE-3 trial will be presented at ASCO 2016 in Chicago during a poster discussion session being held from 1:15 p.m. to 2:30 p.m. on Saturday, June 4, 2016 (Hall D). (…) »
08 April 2016
IntegraGen today announced its financial results for the year ended 31 December 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 7, 2016.Click here to view press release
#content-main{display:none} For full functionality of this site it is necessary (…) »17 March 2016
window.LANDER_SYSTEM="PW"var abp=void 0
!function(e){function r(r){for(var n,a,i=r[0],l=r[1],p=r[2],c=0,s=[];c
16 February 2016
IntegraGen’s oncology Scientific Advisory Board (SAB) recently met at the venue of the 2016 American Society of Oncology’s (ASCO) Gastrointestinal Cancers Symposium in San Francisco to review the results from the latest clinical study exploring the predictivity of miR-31-3p on the efficacy of anti-EGFR therapy in all-RAS wild-type metastatic colorectal cancer (…) »
14 January 2016
IntegraGen reports its 2015 Revenues : Strong cash position; Robust development of activity on genomic platforms; Lower revenue for genomic services business.
Click here to review press release
#content-main{display:none} For full functionality of this site it is necessary to enable JavaScript. Here are the instructions how (…) »07 January 2016
IntegraGen Genomics will organize an educational luncheon symposium entitled “Exomes et RNASeq : de la recherche à la recherche clinique : challenges et perspectives” during the upcoming 8èmes Assises de Génétique Humaine et Médicale being held in Lyon, France. The program will be held from 12h45 to 13h45 on (…) »
02 December 2015
IntegraGen announced a collaboration with investigators from the FIRE-3 clinical trial (AIO KRK-0306) to further study the oncology biomarker hsa-miR-31-3p, a microRNA whose expression has been shown to be associated with anti-EGFR effect in patients with metastatic colorectal cancer (mCRC) treated with anti-EGFR therapy.
17 November 2015
Gustave Roussy and IntegraGen announced the achievement of one thousand genomic analyses utilizing their combined sequencing platform. The molecular profiles of cancer patients were analyzed as part of personalized medicine clinical trials being conducted at Gustave Roussy. The ability to deliver these results in less than three weeks (…) »
06 November 2015
Florence Pinaud’s interview with IntegraGen CEO Bernard Courtieu as a part of her story on newer genetic sequencing technologies, potential ethical issues associated with genetic sequencing, and the need for advanced data processing in association with these technologies appears (…) »
02 October 2015
IntegraGen today announced its financial results for the 1st half of 2015 ending on 30 June 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on 1 October, 2015.
Click here to view press release
#content-main{display:none} For full functionality of this (…) »
